.
.
  • eptinezumab is in phase iii trials. its maker plans to submit an application with the fda later this year. it is for chronic migraine prevention..

    letter exposes 22 lab animal deaths at uc berkeley from 2015 to 2017.

  • .

    now we know the astonishing truth that some patients are waiting a year or more just to get treatment. its simply not good enough..

    see all results matching 'mub'

    Cat wormers as low as $9.95

    Ongoing Discount
    95% Success